Skip to main content
. 2022 Oct 3;74(11):1776–1785. doi: 10.1002/art.42273

Figure 2.

Figure 2

Treatment response rates based on the American College of Rheumatology 20% (ACR20), ACR50, and ACR70 improvement criteria up to week 24. A and B, ACR20, ACR50, and ACR70 improvement response rates at week 16 (A) and week 24 (B). C–E, Changes in ACR20 (C), ACR50 (D), and ACR70 (E) response rates over time. Cochran‐Mantel‐Haenszel test results were used as a stratification factor based on tumor necrosis factor inhibitor usage history. * = P < 0.05; ** = P < 0.01; *** = P < 0.001 versus placebo + methotrexate (MTX).